Michael Bakes

Mick Bakes brings over 20 years of experience in drug development and company operations to DOSE Therapeutics.

Mick has executive experience leading teams supporting General & Administrative functions (IT, HR, legal, accounting, facilities, and safety), Quality Assurance, Regulatory Affairs, and Program Management. He has worked on a number of IND candidates indicated for the treatment of infectious diseases and oncology.

As Vice President, Operations at Peloton Therapeutics, he was involved with all aspects of the company's operations and co-chaired the Product Development Team for its HIF-2a inhibitor being developed in renal cell carcinoma and Von Hippel-Lindau disease. Peloton Therapeutics was acquired by Merck in 2019 and its lead clinical compound (belzutifan, WELIREG) was approved in the US in 2021. Recently he served as Instil Bio's Global Head of Privacy and Data Protection Officer.

Mick received his undergraduate degree in chemistry with honors from the University of Tasmania in 1992.